Teva Launches Generic Symbyax
Symbyax consists of olanzapine, a thienobenzodiazepine, and fluoxetine, a selective serotonin reuptake inhibitor (SSRI). It is indicated in patients with depressive episodes associated with bipolar disorder and treatment-resistant depression. Olanzapine acts as a mood stabilizer as a result of its dopamine type 2 and serotonin type 2 antagonism in the CNS. Fluoxetine exerts its antidepressant effect by potentiating serotonergic activity through highly specific inhibition of neuronal reuptake of serotonin.
Olanzapine and Fluoxetine HCl capsules will be available from Teva in 6mg/25mg, 6mg/50mg, 12mg/25mg, and 12mg/50mg dosage strengths in 30-count bottles.
For more information call (888) 482-9522 or visit www.tevausa.com.